Construction method of high-throughput skeletal muscle organ

By mixing myogenic progenitor cells and fast adherent cells with Matrigel and CaCl2 solutions and forming cell balls coated with calcium alginate capsules, the problem of low efficiency in skeletal muscle organoid construction in the prior art is solved, and rapid and high Throughput production of functional skeletal muscle organoids, suitable for high-throughput pharmaceutical screening research.

CN118909925AActive Publication Date: 2024-11-08LIANGZHU LAB +1
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202411162076.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-23
Publication Date
2024-11-08
Estimated Expiration
2044-08-23

AI Technical Summary

Technical Problem

The existing methods for skeletal muscle organoid construction have long time to form glue and frequent manual operations, which limit the efficiency and operability of high-throughput production, making it difficult to quickly obtain a large number of functional skeletal muscle organoids.

Method used

Mix myogenic progenitor cells and fast adherent cells with Matrigel and CaCl2 solutions to form a cell suspension with a CaCl2 concentration of 0.8 to 1.2%, and add sodium alginate solution to form a Matrigel cell sphere coated with calcium alginate capsules. After coagulation and culture, it is transferred to differentiation medium to induce myogenesis differentiation, achieving rapid and high-throughput skeletal muscle organoid construction.

Benefits of technology

This method simplifies the construction process of skeletal muscle organoids, shortens the construction cycle, and can obtain a large number of (>100) skeletal muscle organoid precursors in a short time (5 minutes), and obtain functional skeletal muscles through inducing differentiation and culture. Organoid, suitable for high-throughput pharmaceutical screening research.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118909925A_ABST
    Figure CN118909925A_ABST
Patent Text Reader

Abstract

The invention discloses a construction method of a high-throughput skeletal muscle organ, which comprises the following steps: uniformly mixing myoblast progenitor cells and rapid adherent cells separated from skeletal muscle with a Matrigel and CaCl2 solution to form a Matrigel cell suspension; adding the Matrigel cell spheres into a sodium alginate solution to obtain Matrigel cell spheres coated with calcium alginate capsules; placing the Matrigel in an incubator to solidify the Matrigel into gel, and placing the Matrigel cell balls coated with the calcium alginate capsules in a growth culture medium to be cultured for 1 day after gel formation; and transferring the Matrigel cell mixture from the growth culture medium to a differential culture medium to induce myogenic differentiation into skeletal muscle organs with a contraction function. The method disclosed by the invention is simple and high in operability, a large number of skeletal muscle organ precursors can be obtained within a short time, and a large number of skeletal muscle organs can be obtained after induced differentiation culture.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of organoid models, and specifically, the present invention relates to a method for constructing a high-throughput organoid, and more specifically, the present invention relates to a method for constructing a high-throughput skeletal muscle organoid. Background Art

[0002] Organoid technology is a method of using the self-organizing properties of mammalian pluripotent stem cells or stem cells from adult tissues to construct 3D cell clusters with multiple cell types in vitro that are similar to the in vivo microenvironment. In recent years, research on organoids of various tissues and organs has been reported. These organoids with multiple cell types and complexity are highly similar to the corresponding tissues and organs in vivo. This technology provides an ideal platform for studying the development, regeneration and pathology of tissues and organs.

[0003] Skeletal muscle organoids are an ideal model for drug screening. Regarding the construction of skeletal muscle organoids, patent CN108660107A discloses a method for constructing skeletal muscle organoids, which includes: 3D co-culturing of myogenic progenitor cells (MPCs) isolated from mouse skeletal muscle with rapidly adherent cells (RACs) in its skeletal muscle in martrigel and obtaining twitching muscle-like tissue blocks after differentiation induction. The method is simple and highly operable. However, the mouse skeletal muscle organoid technology platform in this technology is limited to a certain extent in the high-throughput production of skeletal muscle organoids due to the long gelation time of Matrigel and the need for some steps to be completed manually. Summary of the invention

[0004] The present invention aims to solve the technical problems in the prior art at least to a certain extent. To this end, the present invention provides a high-throughput skeletal muscle organoid construction method.

[0005] The technical solution adopted by the present invention is:

[0006] First,

[0007] The present invention provides a method for constructing a high-throughput skeletal muscle organoid, comprising the following steps:

[0008] (1) Myogenic progenitor cells (MPCs) and rapidly adherent cells (RACs) isolated from skeletal muscle are mixed with Matrigel and CaCl2 solution to form a Matrigel cell suspension with a CaCl2 concentration of 0.8 to 1.2% (w / v);

[0009] (2) adding the Matrigel cell suspension to a 4-6% (w / v) sodium alginate solution to obtain a Matrigel cell sphere coated with calcium alginate capsule (skeletal muscle organoid precursor);

[0010] (3) Placing the Matrigel cell spheres coated with calcium alginate capsules in an incubator to allow the Matrigel to solidify into gel, and then placing the Matrigel cell spheres coated with calcium alginate capsules in a growth medium for culturing for 1 day (to remove the calcium alginate capsules);

[0011] (4) Transfer the Matrigel cell mixture from growth medium to differentiation medium to induce myogenic differentiation into skeletal muscle organoids with contractile function.

[0012] The method of the present invention is to drop a Matrigel cell suspension (MPCs, RACs) mixed with CaCl2 into a sodium alginate solution, and then Ca 2+ Combined with sodium alginate, a layer of calcium alginate capsule is formed on the surface of Matrigel cell suspension to prevent the dissolution and diffusion of Matrigel cell suspension that has not been gelled, and the structure of the inner Matrigel cell ball coated with calcium alginate capsule is formed in the outer layer, so as to achieve the purpose of rapid homogenization and manufacturing Matrigel cell ball; then the Matrigel cell ball (organoid precursor) coated with calcium alginate capsule is placed in a 37°C cell culture incubator to make Matrigel solidify into gel, and after Matrigel gels, the Matrigel cell gel ball coated with calcium alginate capsule is placed in a growth medium and cultured for 1 day, and during the culture process, the phosphate radical in the growth medium dissolves the calcium alginate capsule shell, and then releases the Matrigel cell ball, and can continue to be expanded and cultured in the growth medium, and finally cultured in a differentiation medium for 5-7 days to obtain skeletal muscle organoids. The method of the present invention is simple, highly operable, and a large number of (>100) skeletal muscle organoid precursors can be obtained in a short time (5min), and a large number of skeletal muscle organoids are obtained after induced differentiation culture, which is suitable for high-throughput drug screening research.

[0013] In some embodiments, the skeletal muscle is derived from human or non-human mammals. In a specific embodiment, the skeletal muscle is derived from human or mouse.

[0014] In some preferred embodiments, in step (1), the CaCl2 concentration of the formed Matrigel cell suspension is 1% (w / v).

[0015] In some embodiments, step (1) is: amplifying RACs and MPCs in vitro to 3 to 4 generations; digesting RACs and MPCs with trypsin to form cell suspensions and counting them respectively; taking the required cell suspension, mixing RACs and MPCs in a number ratio of (1 to 2):(1 to 2), centrifuging and removing the supernatant; mixing 4% (w / v) CaCl2 solution with growth medium in a volume ratio of 1:1 to obtain solution A (pre-cooled on ice), and then mixing solution A (pre-cooled on ice) with Matrigel stock solution in a volume ratio of 1:1 on ice to obtain solution B, resuspending the cells with solution B and mixing to obtain a 1% (w / v) CaCl2 Matrigel cell suspension, which is then placed on ice for later use.

[0016] As a preferred example, in step (1), the ratio of the number of RACs to that of MPCs is 1:1.

[0017] In some embodiments, the concentration of the sodium alginate solution in step (2) is 5% (w / v).

[0018] In some embodiments, the composition of the growth medium is: H-DMEM, 5-20% FBS (fetal bovine serum), 0.5-1.5% PS (penicillin-streptomycin), 5-50ng / ml bFGF (basic fibroblast growth factor). Preferably, the composition of the growth medium is: H-DMEM, 10% FBS, 1% PS, 10ng / ml bFGF.

[0019] In some embodiments, the composition of the differentiation induction medium is: H-DMEM, 1-3% HS (horse serum), 100-200 U / ml penicillin, 100-200 U / ml streptomycin. Preferably, the composition of the differentiation induction medium is: H-DMEM, 2% HS, 100 U / ml penicillin, 100 U / ml streptomycin.

[0020] In some embodiments, in step (3), the Matrigel cell spheres coated with calcium alginate capsules are placed in a CO2 incubator at 37°C for 15 to 40 minutes to allow the Matrigel to solidify into a gel.

[0021] In some embodiments, in step (4), the culture time in the differentiation medium is 5 to 7 days. Furthermore, the differentiation medium is replaced every 24 hours. It can be seen that under the method of the present invention, the Matrigel cell sphere is placed in the differentiation medium and cultured for 5 to 7 days to induce myogenic differentiation into skeletal muscle organoids with contractile function. Compared with the prior art, the method of the present invention greatly shortens the construction cycle of skeletal muscle organoids.

[0022] In some embodiments, the myoblast progenitor cells (MPCs) and rapidly adherent cells (RACs) are prepared by a method comprising the following steps:

[0023] 1) Cut the muscle tissue after removing tendons, fat and fascia into pulp; centrifuge and remove the supernatant; wash with HBSS and centrifuge again;

[0024] 2) Remove the supernatant, add 0.2% collagenase XI preheated at 37°C to resuspend the muscle and start digestion. Incubate in a 37°C water bath for 1 hour, mixing by inverting every 10 minutes.

[0025] 3) After the meat slurry-enzyme mixture is centrifuged and the supernatant is removed, it is resuspended in dispase solution and incubated in a 37°C water bath for 1 hour;

[0026] 4) The slurry-enzyme mixture was centrifuged, the supernatant was removed and resuspended with 0.1% trypsin, and incubated in a 37°C water bath for 45 min;

[0027] 5) Centrifuge, remove the supernatant and resuspend in GM;

[0028] 6) Filter the resuspended material through a 70 μm pore size cell sieve;

[0029] 7) Use a syringe to draw up the resuspension;

[0030] 8) Transfer the resuspended solution to the culture dish coated with collagen I and name it PP1;

[0031] 9) After placing in a cell culture incubator at 37°C for 2 hours, transfer the supernatant to a new collagen I-coated 60 mm culture dish named PP2, and add fresh growth medium (GM) to PP1;

[0032] 10) After 24 h, the supernatant in PP2 was transferred to a new collagen I-coated culture dish named PP3, and fresh growth medium was added to PP2;

[0033] 11) Repeat step 10) until PP6 is obtained. After 72 hours in the PP6 culture dish, the supernatant is discarded and replaced with new culture medium;

[0034] The cells in PP1 and PP2 are rapidly adherent cells (RACs); the cells in PP3 and PP4 are myogenic progenitor cells (MPCs) after in vitro purification and expansion.

[0035] In the preparation of the myogenic progenitor cells (MPCs) and the rapidly adherent cells (RACs), the composition of the growth medium is: H-DMEM, 5-20% FBS, 0.5-1.5% PS, 5-50ng / ml bFGF. Preferably, the composition of the growth medium is: H-DMEM, 10% FBS, 1% PS, 10ng / ml bFGF.

[0036] Second,

[0037] The present invention also provides a skeletal muscle organoid obtained by the above method, wherein the diameter of the skeletal muscle organoid is about 1.5 to 2 mm.

[0038] In some embodiments, the skeletal muscle organoid is approximately 1.5 mm in diameter.

[0039] Thirdly,

[0040] The present invention also provides the use of the above-mentioned skeletal muscle organoids for in vitro simulation of injury regeneration research, for screening therapeutic compounds that induce or promote injury regeneration, or as an in vitro model for reconstructing injury-related regeneration processes.

[0041] In a specific embodiment of the use, the skeletal muscle organoids are used for high-throughput screening of therapeutic compounds that induce or promote injury regeneration.

[0042] The beneficial effects of the present invention are:

[0043] (1) The method of the present invention is simple and highly operable. A large number (e.g., >100) of skeletal muscle organoid precursors can be obtained in a short period of time (e.g., 5 minutes). After induced differentiation culture, a large number of skeletal muscle organoids can be obtained.

[0044] (2) The skeletal muscle organoids obtained by the present invention can contract and can be used to quantitatively analyze the physiological functions of skeletal muscle organoids using the moveheat method, which is suitable for high-throughput drug screening research. BRIEF DESCRIPTION OF THE DRAWINGS

[0045] The above and / or additional aspects and advantages of the present invention will become apparent and easily understood from the following description of the embodiments in conjunction with the accompanying drawings, in which:

[0046] Figure 1 Results for the isolation and characterization of human muscle MPCs.

[0047] The left picture shows PAX7 immunofluorescence (red) staining, the middle picture shows DAPI staining, and the right picture shows a merged image of PAX7 immunofluorescence staining and DAPI staining.

[0048] Figure 2The isolated human myogenic progenitor cells can be induced to differentiate into myotubes under 2D culture conditions. Left: MHC (myosin heavy chain) immunofluorescence (green) staining, middle: DAPI staining, right: merged image of MHC immunofluorescence staining and DAPI staining.

[0049] Figure 3 White field image of human skeletal muscle organoids (100×).

[0050] Figure 4 White field image of human skeletal muscle organoids (40×).

[0051] Figure 5 The results are for the isolation and identification of mouse muscle MPCs.

[0052] The left picture shows PAX7 immunofluorescence (red) staining, the middle picture shows DAPI staining, and the right picture shows a merged image of PAX7 immunofluorescence staining and DAPI staining.

[0053] Figure 6 The isolated mouse myogenic progenitor cells can be induced to differentiate into myotubes under 2D culture conditions. Left: MHC (myosin heavy chain) immunofluorescence (green) staining, middle: DAPI staining, right: merged image of MHC immunofluorescence staining and DAPI staining.

[0054] Figure 7 White field image of mouse skeletal muscle organoids (100×).

[0055] Figure 8 White field image of mouse skeletal muscle organoid (40×)

[0056] Fig. 9 The morphological diagrams of Matrigel cell spheres coated with calcium alginate capsules obtained in Example 3 and Comparative Examples 1 and 2 are shown. DETAILED DESCRIPTION

[0057] The present invention illustrates how to implement the present invention by way of examples, which are merely limited enumerations within the spirit of the present invention and do not constitute any limitation to the present invention.

[0058] In order to make the purpose, technical solution and advantages of the embodiment of the present invention clearer, the technical solution of the embodiment of the present invention will be clearly and completely described below. Obviously, the described embodiment is a part of the embodiment of the present invention, not all the embodiments. Based on the described embodiment of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work belong to the protection scope of the present invention.

[0059] Unless otherwise specified, the raw materials and reagents used in the following examples are commercially available or can be prepared by known methods.

[0060] Unless otherwise specified, the scientific and technical terms used herein have the meanings commonly understood by those skilled in the art. In addition, the molecular genetics, nucleic acid chemistry, and immunology laboratory procedures used herein are all conventional procedures widely used in the corresponding fields or are performed according to the conditions recommended by the manufacturers.

[0061] The following is a description of the terminology used in this article:

[0062] As used herein, the term “organoid” refers to miniature organs constructed in a 3D culture environment.

[0063] In this document, in the "first aspect", "second aspect", "third aspect", etc., the terms "first", "second", "third", etc. are used only for descriptive purposes and cannot be understood as indicating or implying relative importance or quantity, nor can they be understood as implicitly indicating the importance or quantity of the indicated technical features. Moreover, "first", "second", "third", "fourth", etc. only serve the purpose of non-exhaustive enumeration and description, and it should be understood that they do not constitute a closed limitation on quantity.

[0064] In this document, references to “preferred”, “more preferred” and “better” are merely intended to describe implementation methods or examples with better effects, and should be understood that they do not limit the scope of protection of the present invention.

[0065] In this document, the terms “further”, “further”, etc. are used for descriptive purposes to indicate differences in content, but should not be construed as limiting the scope of protection of the present invention.

[0066] In this document, the terms "one embodiment", "some embodiments", "examples", "specific examples", or "some examples" etc. mean that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic representations of the above terms do not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described may be combined in any one or more embodiments or examples in a suitable manner. In addition, those skilled in the art may combine and combine the different embodiments or examples described in this specification and the features of the different embodiments or examples, unless they are contradictory.

[0067] Where values ​​are described as a range, it should be understood that such disclosure includes disclosure of all possible sub-ranges within that range, as well as specific values ​​falling within that range, regardless of whether a specific value or a specific sub-range is explicitly stated.

[0068] The present invention provides a high-throughput skeletal muscle organoid construction method, comprising the following steps:

[0069] (1) Myogenic progenitor cells (MPCs) and rapidly adherent cells (RACs) isolated from skeletal muscle are mixed with Matrigel and CaCl2 solution to form a Matrigel cell suspension with a CaCl2 concentration of 0.8 to 1.2% (w / v);

[0070] (2) adding the Matrigel cell suspension to a 4-6% (w / v) sodium alginate solution to obtain a Matrigel cell sphere coated with calcium alginate capsule (skeletal muscle organoid precursor);

[0071] (3) Placing the Matrigel cell spheres coated with calcium alginate capsules in an incubator to allow the Matrigel to solidify into gel, and then placing the Matrigel cell spheres coated with calcium alginate capsules in a growth medium for culturing for 1 day (to remove the calcium alginate capsules);

[0072] (4) Transfer the Matrigel cell mixture from growth medium to differentiation medium to induce myogenic differentiation into skeletal muscle organoids with contractile function.

[0073] For example, the concentration of CaCl2 in the Matrigel cell suspension in step (1) can be 0.8% (w / v), 0.9% (w / v), 1.0% (w / v), 1.1% (w / v), 1.2% (w / v), etc., and the concentration of the sodium alginate solution in step (2) can be 4% (w / v), 4.5% (w / v), 5% (w / v), 5.5% (w / v), 6% (w / v), etc.

[0074] In some embodiments, in step (2), a 1 ml insulin syringe pre-cooled on ice is used to draw up the Matrigel cell suspension, and the syringe piston is slowly pushed to squeeze out the Matrigel cell suspension to form about 8.5 μl droplets, which are then dropped into a 5% (w / v) sodium alginate solution to form a structure in which the outer layer is coated with a calcium alginate capsule and the inner layer is a Matrigel cell sphere.

[0075] In some embodiments, the skeletal muscle is derived from humans or non-human mammals. The non-human mammals include, for example, camels, donkeys, zebras, cattle, pigs, horses, goats, sheep, cats, dogs, rats, rabbits, guinea pigs, mice, non-human primates, etc. The skeletal muscle is derived from humans or mice.

[0076] In some embodiments, the composition of the growth medium is: H-DMEM, 5-20% FBS, 0.5-1.5% PS, 5-50ng / ml bFGF. Non-limiting examples are: the concentration of FBS in the growth medium can be 5%, 8%, 10%, 15%, 20%, etc., the concentration of PS can be 0.5%, 0.8%, 1.0%, 1.2%, 1.5%, etc., the concentration of bFGF can be 5ng / ml, 10ng / ml, 20ng / ml, 30ng / ml, 50ng / ml, etc. Preferably, the composition of the growth medium is: H-DMEM, 10% FBS, 1% PS, 10ng / ml bFGF.

[0077] In some embodiments, the composition of the differentiation induction medium is: H-DMEM, 1-3% HS, 100-200U / ml penicillin, 100-200U / ml streptomycin. Non-limiting examples include: in the differentiation induction medium, the concentration of HS can be 1%, 1.5%, 2%, 2.5%, 3%, etc., the concentration of penicillin can be 100U / ml, 150U / ml, 200U / ml, etc., and the concentration of streptomycin can be 100U / ml, 150U / ml, 200U / ml, etc. Preferably, the composition of the differentiation induction medium is: H-DMEM, 2% HS, 100U / ml penicillin, 100U / ml streptomycin.

[0078] In some embodiments, in step (3), the Matrigel cell spheres coated with calcium alginate capsules are placed in a CO2 incubator at 37°C for 15 to 40 minutes to allow the Matrigel to solidify into a gel.

[0079] In some embodiments, in step (4), the culture time in the differentiation medium is 5 to 7 days. For example, the culture time can be 5 days, 6 days, 7 days, etc., and further, the differentiation medium is replaced once every 24 hours.

[0080] In the present invention, the Moveheat detection method is used to detect the physiological function of skeletal muscle organoids.

[0081] Moveheat detects skeletal muscle organoids:

[0082] 1) Take the mature skeletal muscle organoids out of the incubator and take a video of their contraction under a 40× microscope (about 1 minute);

[0083] 2) After obtaining the video, use the 15*15 average operator to process each frame of the video and blur the image;

[0084] 3) Calculate the grayscale difference between the corresponding pixels of the n+3 frame and the nth frame;

[0085] Finally, the average value of the grayscale change of each pixel in all frames is calculated as the heat of the image change in the corresponding area.

[0086] Example 1

[0087] 1. Isolation of Rapidly Adherent Cells (RACs) and Myogenic Progenitor Cells (MPCs) from Human Skeletal Muscle

[0088] 1) Preheat collagenase Ⅺ (C7657, Sigma-Aldrich), dispase Ⅱ (D4693-1G, Sigma) and trypsin at 37°C;

[0089] 2) Obtain discarded human muscle tissue during orthopedic surgery (from the First Affiliated Hospital of Zhejiang University School of Medicine, obtained with informed consent), wash it three times with HBSS and shave off tendons, fat, and fascia;

[0090] 3) Use ophthalmic scissors to cut the muscle into pulp (about 1mm 3 );

[0091] 4) Transfer the meat slurry to a 15 ml centrifuge tube and centrifuge;

[0092] 5) Remove the supernatant, wash with HBSS (24020-117, Invitrogen) and centrifuge again;

[0093] 6) Remove the supernatant, add 10 ml of 0.2% collagenase Ⅺ preheated at 37°C to resuspend the muscle and start digestion. Incubate in a 37°C water bath for 1 hour, mixing by inverting every 10 minutes.

[0094] 7) Centrifuge the slurry-enzyme mixture at 930 g for 5 min at 4°C, remove the supernatant and resuspend in 10 ml of dispase solution, incubate in a 37°C water bath for 1 hour, inverting and mixing every 10 min;

[0095] 8) Centrifuge the slurry-enzyme mixture at 930 g for 5 min at 4°C, remove the supernatant, resuspend with 10 ml of 0.1% trypsin, and incubate in a 37°C water bath for 45 min, mixing every 10 min (gently);

[0096] 9) Centrifuge at 930 g for 5 min at 4°C, remove the supernatant and resuspend in 10 ml GM;

[0097] 10) Filter the resuspended material through a 70 μm pore size cell sieve;

[0098] 11) Use 18G, 23G and 27G 10ml syringes to draw up the resuspension (twice each);

[0099] 12) Transfer the resuspended solution to a 60 mm culture dish coated with collagen I and name it PP1;

[0100] 13) After placing in a cell culture incubator at 37°C for 2 hours, transfer the supernatant to a new collagen I-coated 60 mm culture dish named PP2, and add 3 ml of fresh growth medium (GM) to PP1;

[0101] The composition of the growth medium was: H-DMEM, 10% FBS, 1% PS, 10 ng / ml bFGF;

[0102] 14) After 24 h, transfer the supernatant in PP2 to a new collagen I-coated 60 mm culture dish named PP3, and add 3 ml of fresh growth medium to PP2;

[0103] 15) Repeat step 14) until PP6 is obtained. After 72 hours in the PP6 culture dish, the supernatant is discarded and replaced with new growth medium.

[0104] The cells in PP1 and PP2 are rapidly adherent cells (RACs), and their cell morphology is very similar to that of fibroblasts; most of the cells in PP3 and PP4 are muscle stem cells, which become myogenic progenitor cells, i.e., MPCs, after in vitro purification and expansion.

[0105] 2. MPCs in vitro purification steps:

[0106] 1) Aspirate the culture medium and wash with 2 ml 1X PBS;

[0107] 2) Digest with 0.5 ml 0.05% trypsin at 37°C for 30 s, then add 0.5 ml GM to terminate digestion;

[0108] 3) Transfer the digested cells to a 15 ml centrifuge tube and centrifuge at 930 g for 5 min;

[0109] 4) Aspirate the supernatant, add 3 ml GM to resuspend the cells and transfer the cell suspension to a new 60 mm collagen I-coated culture dish, then place the culture dish in the incubator to adhere to the wall for 30 minutes;

[0110] 5) After 30 minutes of adhesion treatment, the non-adherent cells in the supernatant were transferred to a new 60 mm collagen I-coated culture dish.

[0111] At this point, one purification is completed, and the number of times the purification is repeated depends on the degree of contamination of the fibroblast-like cells.

[0112] 3. Identification of MPCs

[0113] PAX7 is a classic marker for muscle stem cells, so this application uses this marker to identify the isolated muscle stem / progenitor cells.

[0114] Figure 1 The results of the isolation and identification of human muscle MPCs. Figure 1 Immunofluorescence results of PAX7 + The ratio of the cell number to the total cell number showed that myogenic progenitor cells with high purity (>95%) were isolated.

[0115] Figure 2 The results of the isolated human myogenic progenitor cells in 2D culture conditions were Figure 2 It can be seen that the human myogenic progenitor cells separated by the method of Example 1 can be induced to differentiate into myotubes under 2D culture conditions.

[0116] The 2D culture conditions are as follows: growth medium (H-DMEM, 10% FBS, 1% PS, 10 ng / ml bFGF); culture dishes coated with rat tail collagen I; cultured in a cell box at 37° C. and 5% CO 2 .

[0117] Example 2

[0118] The difference from Example 1 is that Example 2 is directed to mouse skeletal muscle.

[0119] That is, in the first part, step 2) is: two 6-8 week old C57BL / 6 male mice (Experimental Animal Center, School of Medicine, Zhejiang University) were killed by vertebral fracture and sterilized in 75% alcohol for 10 minutes; the gastrocnemius and tibialis anterior muscles of the hind limbs were taken, washed three times with HBSS and the tendons, fat and fascia were shaved off.

[0120] The other steps are the same as in Example 1.

[0121] Figure 5 The results are the results of the isolation and identification of mouse muscle MPCs. Figure 5 Immunofluorescence results of PAX7 + The calculation of the ratio of the cell number to the total cell number shows that mouse myogenic progenitor cells with high purity (>90%) were isolated.

[0122] Figure 6 The results of the isolated mouse myogenic progenitor cells in 2D culture conditions were Figure 6 It can be seen that the mouse myogenic progenitor cells isolated by the method of Example 2 can be induced to differentiate into myotubes under 2D culture conditions.

[0123] The 2D culture conditions are as follows: growth medium (H-DMEM, 10% FBS, 1% PS, 10 ng / ml bFGF); culture dishes coated with rat tail collagen I; cultured in a cell box at 37° C. and 5% CO 2 .

[0124] Example 3 Preparation of skeletal muscle organoids

[0125] 1) Pre-cool the growth medium and Matrigel on ice 30 min in advance;

[0126] 2) Dilute Matrigel 1-fold with growth medium according to the required amount and continue precooling on ice;

[0127] 3) The RACs and MPCs prepared in Example 1 were expanded in vitro to the third or fourth generation, so that the RACs and MPCs could each reach at least 7*10 5 ;

[0128] 4) digest RACs and MPCs with trypsin into cell suspensions and count them separately;

[0129] 5) Determine the amount of RACs and MPCs to be used according to the number of organoids to be produced (RACs:MPCs = 1:1), then take the required cell suspension, mix RACs and MPCs in a 1:1 ratio, and add 1.4*10 RACs and 1.4*10 MPCs respectively. 5 After centrifugation at 200 g for 5 min, the supernatant was removed.

[0130] 6) Mix 4% (w / v) CaCl2 with growth medium at a volume ratio of 1:1 to obtain solution A (pre-cooled on ice), then mix solution A (pre-cooled on ice) with Matrigel stock solution at a volume ratio of 1:1 on ice to obtain solution B, resuspend cells in solution B and mix to obtain a Matrigel cell suspension with a concentration of 1% (w / v) CaCl2, and then put on ice for later use;

[0131] 7) Use a 1 ml insulin syringe pre-cooled on ice to absorb the Matrigel cell resuspension, slowly push the syringe piston to squeeze out the Matrigel cell suspension to form a droplet ball (about 8.5 μl), and drop the droplet ball into a 5% (w / v) sodium alginate solution to form a structure in which the outer layer is coated with a calcium alginate capsule and the inner layer is a Matrigel cell ball. Then, place the Matrigel cell ball coated with the calcium alginate capsule in a 37°C CO2 incubator for 20 minutes to allow the Matrigel to solidify into a gel;

[0132] 8) After the Matrigel solidifies into a gel, the Matrigel cell spheres coated with calcium alginate capsules are placed in growth medium (H-DMEM, 10% FBS, 1% PS, 10 ng / ml bFGF) for suspension culture for 24 h (the calcium alginate capsules are automatically removed);

[0133] 9) The Matrigel cell mixture was transferred from the growth medium to the differentiation medium (H-DMEM, 2% HS, 100 U / ml penicillin, 100 U / ml streptomycin) and cultured for 7 days (the differentiation medium was changed every 24 hours) to obtain human skeletal muscle organoids.

[0134] By using the method of Example 3, a twitching human skeletal muscle organoid can be obtained. Figure 3 This is a white field image of human skeletal muscle organoids (100×). Figure 4 This is a white field image of human skeletal muscle organoids (40×). Figure 3 , Figure 4 It can be seen that the diameter of the cultured human skeletal muscle organoids is about 1.5 mm.

[0135] Example 4

[0136] The difference from Example 3 is that Example 4 uses the RACs and MPCs prepared in Example 2 to prepare mouse skeletal muscle organoids.

[0137] By using the method of Example 4, a mouse skeletal muscle organoid that can twitch can be obtained. Figure 7 This is a white field image of mouse skeletal muscle organoids (100×). Figure 8 This is a white field image of mouse skeletal muscle organoids (40×). Figure 7 , Figure 8 It can be seen that the diameter of the cultured mouse skeletal muscle organoids is about 1.5 mm.

[0138] Comparative Example 1

[0139] The difference from Example 3 is that the concentration of the sodium alginate solution is 1.25% (w / v).

[0140] Comparative Example 2

[0141] The difference from Example 3 is that the concentration of the sodium alginate solution is 10% (w / v).

[0142] The morphology of the Matrigel cell spheres coated with calcium alginate capsules obtained in Example 3, Comparative Example 1 and Comparative Example 2 is shown in the figure below: Fig. 9 As shown, through Fig. 9It can be seen that the shape uniformity of the calcium alginate capsule-coated Matrigel cell spheres obtained by dropping the Matrigel cell suspension containing 1% (w / v) CaCl2 concentration into 1.25% (w / v) and 10% (w / v) sodium alginate solutions is not as good as the shape uniformity of the calcium alginate capsule-coated Matrigel cell spheres obtained by dropping into 5% (w / v) sodium alginate solution, and the calcium alginate capsule-coated Matrigel cell spheres obtained in 5% (w / v) sodium alginate solution are hemispherical in shape, while the calcium alginate capsule-coated Matrigel cell spheres obtained in 1.25% (w / v) and 10% (w / v) sodium alginate solutions are flaky in shape, which is not conducive to the subsequent cell self-organization to produce functional muscle organoids.

[0143] Although the embodiments of the present invention have been shown and described above, it is to be understood that the above embodiments are exemplary and are not to be construed as limitations of the present invention. A person skilled in the art may change, modify, replace and vary the above embodiments within the scope of the present invention.

Claims

1. A method for constructing high-throughput skeletal muscle organoids, characterized in that: The steps include: (1) Myogenic progenitor cells (MPCs) and rapidly adherent cells (RACs) isolated from skeletal muscle are mixed with Matrigel and CaCl2 solution to form a Matrigel cell suspension with a CaCl2 concentration of 0.8-1.2% w / v; (2) adding the Matrigel cell suspension to a 4-6% w / v sodium alginate solution to obtain a Matrigel cell sphere coated with calcium alginate capsule; (3) placing the Matrigel cell spheres coated with calcium alginate capsules in an incubator to allow the Matrigel to solidify into gel, and after gelation, placing the Matrigel cell spheres coated with calcium alginate capsules in a growth medium and culturing for 1 day to remove the calcium alginate capsules; (4) Transfer the Matrigel cell mixture from growth medium to differentiation medium to induce myogenic differentiation into skeletal muscle organoids with contractile function.

2. A method for constructing a high-throughput skeletal muscle organoid according to claim 1, characterized in that: The skeletal muscle is derived from humans or non-human mammals; Optionally, the skeletal muscle is derived from human or mouse.

3. A method for constructing a high-throughput skeletal muscle organoid according to claim 1, characterized in that: In step (1), the CaCl2 concentration of the formed Matrigel cell suspension is 1% w / v; Preferably, step (1) comprises: amplifying RACs and MPCs in vitro to 3-4 generations; digesting RACs and MPCs with trypsin to form cell suspensions and counting them respectively; taking the required cell suspension, mixing RACs and MPCs in a number ratio of (1-2):(1-2), centrifuging and removing the supernatant; mixing 4% w / v CaCl2 solution with growth medium in a volume ratio of 1:1 to obtain solution A, and then mixing solution A with Matrigel stock solution in a volume ratio of 1:1 on ice to obtain solution B, resuspending the cells with solution B and mixing to obtain a 1% w / v CaCl2 Matrigel cell suspension, and then placing on ice for later use; More preferably, in step (1), the ratio of the number of RACs to that of MPCs is 1:

1.

4. A method for constructing a high-throughput skeletal muscle organoid according to claim 1, characterized in that: In step (2), the concentration of the sodium alginate solution is 5% w / v.

5. A method for constructing a high-throughput skeletal muscle organoid according to claim 1, characterized in that: The composition of the growth medium is: H-DMEM, 5-20% FBS, 0.5-1.5% PS, 5-50ng / ml bFGF; Preferably, the growth medium consists of: H-DMEM, 10% FBS, 1% PS, 10 ng / ml bFGF.

6. A method for constructing a high-throughput skeletal muscle organoid according to claim 1, characterized in that: The differentiation induction medium is composed of: H-DMEM, 1-3% HS, 100-200 U / ml penicillin, and 100-200 U / ml streptomycin; Preferably, the differentiation induction medium consists of: H-DMEM, 2% HS, 100 U / ml penicillin, and 100 U / ml streptomycin.

7. A method for constructing a high-throughput skeletal muscle organoid according to claim 1, characterized in that: In step (3), the Matrigel cell sphere coated with calcium alginate capsule is placed in a CO2 incubator at 37°C for 15 to 40 minutes to allow the Matrigel to solidify into a gel.

8. A method for constructing a high-throughput skeletal muscle organoid according to claim 1, characterized in that: In step (4), the culture time in the differentiation medium is 5 to 7 days.

9. A skeletal muscle organoid, characterized in that: A skeletal muscle organoid constructed by the construction method according to any one of claims 1 to 8, wherein the diameter of the skeletal muscle organoid is 1.5 to 2 mm; Optionally, the skeletal muscle organoid is approximately 1.5 mm in diameter.

10. The use of the skeletal muscle organoid according to claim 9, wherein the skeletal muscle organoid is used for in vitro simulation of injury and regeneration research, for screening therapeutic compounds that induce or promote injury and regeneration, or as an in vitro model for reconstructing injury-related regeneration processes; Furthermore, the skeletal muscle organoids are used for high-throughput screening of therapeutic compounds that induce or promote injury regeneration.

Citation Information

Patent Citations

  • Construction method of skeletal muscle organ

    CN108660107A

  • In vitro expansion method for stem cells

    CN112522183A

  • Method for coating in-vitro living tissue with micron-sized calcium alginate gel

    CN117025509A